

CONTENTS

NOTE TO THE READER.....	1
LIST OF PARTICIPANTS.....	3
PREAMBLE.....	9
Background.....	9
Objective and Scope.....	9
Selection of Topics for Monographs.....	10
Data for Monographs.....	11
The Working Group.....	11
Working Procedures.....	11
Exposure Data.....	12
Studies of Cancer in Humans.....	14
Studies of Cancer in Experimental Animals.....	17
Other Data Relevant to an Evaluation of Carcinogenicity and Its Mechanisms.....	19
Summary of Data Reported.....	21
Evaluation.....	22
References.....	26
GENERAL REMARKS.....	31
THE MONOGRAPH	
Human papillomaviruses	
1. Human papillomavirus (HPV) infection.....	35
1.1 Structure and molecular biology of human papillomaviruses.....	35
1.1.1 Structure of the viruses.....	35
1.1.2 Taxonomy.....	36
1.1.3 Genomic variability.....	39
1.1.4 Host range.....	39
1.1.5 Related animal papillomaviruses.....	40
1.1.6 Target tissues.....	40
1.1.7 Genomic structure and properties of gene products.....	40
1.1.8 Regulation of gene expression.....	43
1.1.9 Replication.....	47
1.2 Serological response.....	47
1.2.1 Antigenic properties of HPVs.....	47

1.2.2	Immune response to papillomavirus infections	49
	(a) Initial studies	49
	(b) Use of genetically engineered or synthetic viral antigens in serological assays	49
1.3	Methods for detection of HPV infections	52
1.3.1	HPV diagnosis by morphology	52
1.3.2	Detection of HPV proteins in infected tissues	53
1.3.3	Detection of HPV genomic sequences	53
	(a) PCR-based methods	53
	(b) ViraPap™ and Hybrid Capture™	55
	(c) Southern blot hybridization	56
	(d) In-situ hybridization	56
	(e) Filter in-situ hybridization	56
	(f) Comparison of HPV testing methods	57
1.3.4	Detection of HPV infections and HPV-associated cancers by serological assays	57
1.4	Epidemiology of infection	58
1.4.1	Transmission	58
1.4.2	Incidence	60
1.4.3	Prevalence	61
1.4.4	Natural history	65
1.5	Pathology of HPV genital tract infection and evidence from pathology for progression to malignancy	66
1.5.1	Terminology	67
	(a) Dysplasia and carcinoma <i>in situ</i>	67
	(b) Cervical intraepithelial neoplasia (CIN)	67
	(c) Squamous intraepithelial lesion (SIL)	69
	(d) Other organs in the male and female anogenital tract	70
1.5.2	Temporal and spatial relationships between cervical cancer precursors and invasive cancer	70
	(a) Histological observations	70
	(b) Microinvasive and early invasive cervical cancers	70
	(c) Clinical observations	70
1.5.3	Histological changes in HPV-related lesions of the lower female genital tract	71
	(a) Non-productive (latent) HPV infection	71
	(b) Low-grade CIN	71
	(c) High-grade CIN	74
	(d) Microinvasive and invasive squamous-cell cancer of the cervix	75
	(e) Vaginal intraepithelial neoplasia	76
	(f) Vulva	77
	(g) Vagina, anus and penis	78
	(h) Adenocarcinoma <i>in situ</i> and adenocarcinoma	78

1.5.4	Pathology of non-melanoma skin cancer and cutaneous HPV infection ...	79
	(a) Cutaneous HPV infection	79
	(b) Non-melanoma skin cancer	79
1.5.5	Pathology of HPV-induced changes in the nude mouse system and tissue culture studies	80
1.6	Clinical disease of established HPV etiology (other than precancer and cancer)...	80
1.6.1	Genital area	80
1.6.2	Upper respiratory and digestive tract and conjunctiva.....	81
1.6.3	Skin	82
1.7	Therapy and vaccination	83
1.7.1	Therapy of benign disease.....	83
1.7.2	Therapy of precancers	84
1.7.3	Vaccination	86
2.	Studies of cancer in humans	87
2.1	Descriptive studies of anogenital cancer.....	88
2.1.1	Cancer of the uterine cervix	88
2.1.2	Other anogenital cancers	89
2.2	Case reports and case series	91
2.2.1	Cancer of the uterine cervix	91
	(a) Pre-invasive cervical lesions	91
	(b) Squamous-cell carcinoma	91
	(c) Adenocarcinoma and adenosquamous carcinoma	99
	(d) Geographical and temporal variation	99
2.2.2	Anogenital cancers	103
	(a) Cancer of the vulva and vagina.....	103
	(b) Cancer of the penis.....	107
	(c) Cancer of the anus.....	107
2.2.3	Other cancers.....	107
	(a) Oral cancer	114
	(b) Cancer of the pharynx and tonsil	114
	(c) Oesophageal cancer.....	114
	(d) Cancer of the colon and rectum	114
	(e) Nasal/sinonasal cancer	114
	(f) Laryngeal cancer	114
	(g) Lung cancer.....	121
	(h) Cancer of the skin	121
	(i) Breast cancer	123
	(j) Ovarian cancer	123
	(k) Cancer of the bladder and urethra	130
	(l) Prostate cancer	130
	(m) Cancer of the eye.....	130
2.3	Cohort studies	130
2.3.1	Following HPV DNA detection in normal women to cytological diagnosis of CIN	133

2.3.2	Following mild dysplasia/koilocytotic atypia to CIN III/invasive cancer	135
	(a) Prospective studies of mild dysplasia/koilocytotic atypia without HPV DNA testing	135
	(b) Prospective studies of mild dysplasia/koilocytotic atypia with HPV DNA testing	138
2.3.3	Prospective studies of HPV infection at body sites other than the cervix	141
2.4	Case-control studies	141
2.4.1	Cervical cancer	142
	(a) HPV and CIN III	142
	(b) HPV and invasive cancer of the uterine cervix	163
2.4.2	Other cancers	184
	(a) Anogenital cancers	184
	(b) Other cancers	189
2.4.3	Cofactors	194
2.5	Special populations	196
2.5.1	Skin cancer in patients with epidermodysplasia verruciformis (EV)	196
	HPV types in warts and skin cancers in EV patients	197
2.5.2	Studies of cancer incidence in transplant patients	200
	(a) HPV infection, CIN and invasive cervical and anogenital carcinoma in transplant recipients	200
	(b) HPV DNA in transplant-associated skin lesions	204
	(c) HPV infection and cancer at other sites	212
2.5.3	Studies in HIV-infected persons	212
	(a) Studies of the uterine cervix	214
	(b) Studies of the anorectal region	222
3.	Molecular mechanisms of carcinogenesis	233
3.1	Experimental data supporting the carcinogenicity of specific HPV genotypes and analysing the mechanism of HPV-linked carcinogenesis	233
3.1.1	Low-risk and high-risk HPV infections	233
3.1.2	Chromosomal instability of high-risk HPV-infected cells	233
3.1.3	Immortalization and transformation of cells by HPVs	234
	(a) Contribution of viral and cellular genes	234
	(b) Chromosomal abnormalities in HPV-immortalized cells	235
	(c) Transcriptional modulation by HPV oncoproteins	236
	(d) Positive and negative transforming functions of HPV	236
	(e) HPV-targeted cellular proteins in cervical carcinogenesis	240
3.1.4	Experimental evidence for a role of high-risk HPVs in malignant conversion and in human cervical cancers	242
	(a) Requirement for HPV gene expression for invasive growth and the malignant phenotype	242
	(b) Integration of HPV sequences	243
	(c) Chromosomal abnormalities in HPV-associated cancers	244
	(d) Alterations of specific proto-oncogenes	245

3.1.5	Interactions between HPV and environmental agents	246
	(a) Interaction with other viruses.....	246
	(b) Hormones and antioestrogens	248
	(c) Chemicals.....	249
	(d) Radiation	250
3.1.6	HPV in mice.....	251
	(a) HPV recombinant retrovirus	251
	(b) HPV transgenic mice	251
3.2	Immune mechanisms and HPV-associated neoplasia.....	253
3.2.1	Immunosuppression	253
3.2.2	Histological studies	254
3.2.3	Cell-mediated immunity	255
	(a) Helper T-cell responses.....	255
	(b) Cytotoxic T-cell responses.....	256
3.2.4	Major histocompatibility complex (MHC) expression	257
	(a) MHC class I	257
	(b) MHC class II	258
3.2.5	HLA polymorphisms: association with cervical cancer risk.....	259
4.	Studies of cancer in animals.....	261
4.1	Non-human primate papillomavirus	261
	Rhesus monkey genital papillomavirus	261
4.2	Bovine papillomavirus.....	263
4.2.1	Heterogeneity of bovine papillomavirus.....	263
4.2.2	BPV-1.....	263
	(a) BPV-1 in hamsters	264
	(b) BPV-1 in transgenic mice	264
4.2.3	BPV-2.....	264
	(a) BPV-2 in bladder cancers	264
	(b) BPV-2 latency	265
	(c) BPV-2 in hamsters	267
4.2.4	BPV-3.....	267
4.2.5	BPV-4.....	267
	(a) BPV-4 and alimentary tract cancer	267
	(b) BPV-4 in mouse xenografts	268
	(c) BPV-4 in hamsters	268
4.2.6	BPV-5 and BPV-6.....	269
4.2.7	Bovine ocular squamous-cell carcinoma (OSCC)	269
4.2.8	Bovine skin carcinoma.....	269
4.2.9	BPV in equine sarcoids	270
4.3	Equine papillomavirus (EqPV).....	271
4.4	Papillomaviruses in cervidae	271
4.5	Ovine papillomatosis	272
4.6	Cottontail rabbit papillomavirus (CRPV).....	273
4.6.1	CRPV and co-carcinogens	273

4.6.2	CRPV latency.....	274
4.6.3	CRPV in transgenic rabbits.....	274
4.7	Domestic rabbit oral papillomavirus.....	275
4.8	<i>Mastomys natalensis</i> papillomavirus (MnPV).....	275
4.9	Mouse papillomavirus (MmPV).....	275
4.10	Canine oral papillomavirus (COPV).....	276
4.11	Feline papillomas.....	276
4.12	Avian papillomavirus.....	276
5.	Summary of data reported and evaluation.....	277
5.1	HPV infection.....	277
5.2	Studies of cancer in humans.....	278
5.3	Molecular mechanisms of carcinogenesis.....	280
5.4	Studies of cancer in animals.....	281
5.5	Evaluation.....	281
6.	References.....	283
SUPPLEMENTARY CORRIGENDA TO VOLUMES 1–63.....		379
CUMULATIVE INDEX TO THE <i>MONOGRAPHS</i> SERIES.....		381

NOTE TO THE READER

The term 'carcinogenic risk' in the *IARC Monographs* series is taken to mean the probability that exposure to an agent will lead to cancer in humans.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Unit of Carcinogen Identification and Evaluation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Unit of Carcinogen Identification and Evaluation, so that corrections can be reported in future volumes.